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Abstract
Stevens–Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) represent rare
but serious adverse drug reactions (ADRs). Both are characterized by distinctive blistering
lesions and significant mortality rates. While there is evidence for strong drug-specific
genetic predisposition related to HLA alleles, recent genome wide association studies
(GWAS) on European and Asian populations have failed to identify genetic susceptibility
alleles that are common across multiple drugs. We hypothesize that this is a consequence
of the low to moderate effect size of individual genetic risk factors. To test this hypothesis
we developed Pointer, a new algorithm that assesses the aggregate effect of multiple low
risk variants on a pathway using a gene set enrichment approach. A key advantage of our
method is the capability to associate SNPs with genes by exploiting physical proximity as
well as by using expression quantitative trait loci (eQTLs) that capture information about
both cis- and trans-acting regulatory effects. We control for known bias-inducing aspects of
enrichment based analyses, such as: 1) gene length, 2) gene set size, 3) presence of bio-
logically related genes within the same linkage disequilibrium (LD) region, and, 4) genes
shared among multiple gene sets. We applied this approach to publicly available SJS/TEN
genome-wide genotype data and identified the ABC transporter and Proteasome pathways
as potentially implicated in the genetic susceptibility of non-drug-specific SJS/TEN. We
demonstrated that the innovative SNP-to-gene mapping phase of the method was essential
in detecting the significant enrichment for those pathways. Analysis of an independent gene
expression dataset provides supportive functional evidence for the involvement of Protea-
some pathways in SJS/TEN cutaneous lesions. These results suggest that Pointer provides
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a useful framework for the integrative analysis of pharmacogenetic GWAS data, by increas-
ing the power to detect aggregate effects of multiple low risk variants. The software is avail-
able for download at https://sourceforge.net/projects/pointergsa/.
Introduction
Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare, life-threaten-
ing adverse drug reactions (ADRs) with a worldwide incidence of 1 to 4 cases over 1 million
people per year [1]. SJS and TEN are variants of the same muco-cutaneous eruption, character-
ized by a rapidly developing blistering skin detachment. The extent of blistering is proportional
to the increase in mortality rate, which is estimated between 10% and 30%.[1] SJS/TEN is a
multi-drug induced hypersensitivity reaction, [1,2] promoted by a major histocompatibility
class I–restricted drug clonal expansion of cytotoxic T lymphocytes (CTLs) [3]. Human leuco-
cyte antigen (HLA) haplotypes have been implicated in drug-specific susceptibility, sometimes
in an ethnicity-dependent manner. For instance, HLA-B1502 and HLA-A3101 are predictive
markers for carbamazepine (CMZ)-induced SJS/TEN respectively in Asians [4,5] and Europe-
ans [6], while HLA-B5801 for allopurinol-induced SJS/TEN in both populations [7,8]. How-
ever, recent genome wide association studies (GWAS) on both Asian and European
populations have failed to identify highly penetrant genetic risk factors associated with SJS/
TEN across multiple drugs [9,10].
These negative findings suggest that if adverse response across many drugs is mediated by a
common genetic mechanism, this mechanism is probably due to factors with small or moder-
ate effect sizes. Non-drug-specific genetic susceptibility might modify the HLA related drug-
specific predisposition and explain the localization of the cutaneous lesions. Unfortunately, the
rarity of SJS/TEN limits the number of available samples and adversely affects the power of tra-
ditional GWASs to detect risk factors with moderate-to-low risk. Gene Set Analysis (GSA)
methods attempt to work around the limitations of single locus association analysis by evaluat-
ing the aggregate effect of variants, specifically by investigating if genetic variation preferen-
tially targets genes that are functionally related. [11,12] The underlying assumption is that
although polygenic traits are due to the combined effect of multiple loci, their effect must coa-
lesce through a smaller number of common biological processes. Following this hypothesis,
GSA approaches that leverage GWAS hits are becoming increasingly popular in the study of
unexplained hereditability [11,12].
However, results of GSA can suffer from several sources of bias, such as: 1) inaccurate SNP
to gene mapping, 2) lack of correction for gene set size and gene and LD block length, 3) bio-
logical interdependence of genes within the same LD region, and 4) redundancies in gene set
composition. [11,12] Here we present Pointer, an integrative GSA-based approach that over-
comes these limitations. Pointer introduces several methodological innovations. First, it maps
SNPs to genes using information both from LD structure and from expression quantitative
trait loci that account for long-range regulatory effects. We demonstrate that the combination
of these two sources of evidence leads to improved power to detect pathways that are enriched
in genes harboring putative causal variants. Second, it uses a modified version of the Gene Set
Enrichment Analysis (GSEA) algorithm [13] for calculating enrichment scores, controlling for
gene set size, gene length, and for positive inflation due to long LD regions that contain biologi-
cally related genes, and utilizing a rigorous randomization process for the computation of the
null distribution for the enrichment scores. Third, it eliminates spurious enrichment caused by
SJS/TENGenetic Susceptibility
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compositional redundancy, e.g., when the gene sets of two pathways significantly overlap but
only one of them is relevant for the phenotype.
We evaluated Pointer by analyzing genotyping data from a previously published SJS/TEN
genome-wide association study [10]. We found the ABC transporters pathway to be signifi-
cantly enriched for low risk genetic variants (FDR = 0.06). Members of the ABC transporter
family have previously been implicated in hereditable skin disease and may play a role in drug
metabolism and the tissue-specific localization of the ADR [14]. Two more pathways, the pro-
teasome complex and propanoate metabolism pathways, were only marginally enriched
(FDR = 0.25). However, in the case of the proteasome complex we were able to find indepen-
dent functional evidence that corroborates its role in the pathogenesis of the SJS/TEN. Specifi-
cally, using published gene expression data, we found the proteasome complex to be enriched
in genes differentially expressed in white cells located in the blistering active lesion when com-
pared to peripheral white cells. We suggest that Pointer is a suitable tool to test the aggregate
effect of markers in GWASs, especially in pharmacogenetic studies of adverse drug reactions
where power can be hampered by relatively small sample sizes.
Materials and Methods
Genome-wide genotype data
We analyzed previously published GWAS results from 72 Caucasian SJS cases and 461
matched controls [10] genotyped with Illumina’s Human 1M BeadChip (see S1 File). Low
quality SNPs were eliminated using standard quality control procedures (excluding markers
with MAF< 0.01 and GenTrain score< 0.6). The association of SNPs to the ADR phenotype
was calculated by logistic regression, using the top four principal components as covariates to
account for population structure. Details of all analysis steps are available in [10].
Expression QTL data
We used previously published liver-specific eQTL data [15] to account for genetic factors that
affect drug catabolism and transport and which could contribute to SJS/TEN pathogenicity via
the hapten-mediated mechanism [16], i.e., by enabling the formation of hapten-protein
adducts that can elicit an immune response. The association between the adjusted liver expres-
sion levels and the genotypes was determined using the Kruskal-Wallis test and corrected for
multiple-hypothesis testing. Significant associations were selected based on FDR 0.1. The
original publication [15] provides the full details of the eQTL analysis.
Pathway databases
We used the Kyoto Encyclopedia of Genes and Genomes (KEGG, release December 2010)
which contains information for a variety of metabolic pathways, and the Reactome pathway
database (release 36). The two pathway collections were chosen on the basis of being manually
curated, thus ensuring high quality content. Data was downloaded from the Molecular Signa-
ture Database (MSigDB, version 3 of the C2-collections; www.broad.mit.edu/gsea/msigdb/
msigdb_index.html).
Gene expression data from SJS lesions
Chung et al. used the Affymetrix Human Genome U133 Plus 2.0 GeneChip to profile five sam-
ples of blister fluid white cells from subjects with multidrug SJS/TEN and six samples of periph-
eral blood mononuclear cells (PBMCs) [GSE13816], and reported the 200 most differentially
SJS/TENGenetic Susceptibility
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expressed genes (DEGs). [3] We used DAVID [17] to calculate the enrichment of canonical
pathways for those 200 DEGs.
SNP to gene mapping
We used LD structure and eQTL information to map each genotyped SNP to all genes whose
function or regulation that SNP (or one of its co-inherited variants) could potentially affect.
First, the LD structure around each genotyped SNP was reconstructed. To that end, we utilized
the HapMap CEU II SNP reference panel (release 22) which includes 3,572,677 common SNPs
(minor allele frequency> 0.01, NCBI Build 36). Using the Haploview software [18], we com-
puted the r2 between every genotyped SNP and all HapMap II SNPs within a 4 MB window (a
large window size was chosen to capture both proximal and distant co-inhered variants). All
HapMap II SNPs having an r2 0.5 were grouped together to define a LD cluster for the geno-
typed SNP. Finally, genes were assigned to every SNP in a LD cluster based on: 1) Physical dis-
tance: a gene was assigned to a SNP if the SNP was located within 1500 bp upstream or
downstream of the gene’s longest known transcript (gene transcript RefSeq annotation was
downloaded from UCSC (hg18) [19] and mitochondrial genes coordinates from NCBI, RefSeq
accession NC_012920.1); 2) Putative regulatory effect on liver gene expression: a gene was
assigned to a SNP if the corresponding liver eQTL revealed a significant association (at
FDR 0.1) of the SNP to the expression of the gene.
We define the set of all genes assigned to a genotyped SNP X by the process described above
to be the “SNP gene map” of X, denoted as snp-map, and call X the representative SNP of the
snp-map.
Pathway enrichment analysis
Pointer uses a variant of the Gene Set Enrichment Analysis (GSEA) [13] to assess if a given
pathway is enriched for GWAS SNPs. GSEA was originally developed for microarray analysis,
to test whether genes in a set are collectively differentially expressed, even if no single gene
achieves statistical significance on its own. Briefly, the input to GSEA is a set of genes S (e.g.,
genes in a pathway) and an ordered gene list L, where genes in L are ranked by the strength of
their differential expression. GSEA determines whether the members of S are randomly distrib-
uted throughout L or primarily clustered at the top or bottom of the ordered list.
Our approach carefully corrects for known biases of GSA-based methods [11,12]. Such
methods usually begin by mapping SNPs to genes and then rank genes according to the GWAS
p-value of their mapped SNPs. However, the many-to-many nature of the SNP-to-gene map-
ping step can be a source of bias [20], as ranking is often performed by choosing the smallest p-
value among all the SNPs mapped to a gene. This strategy favors longer genes which typically
have more SNPs mapped to them, leading to systematic assignment of a smaller p-value to lon-
ger genes compared to shorter genes. The same problem exists for methods that use LD-struc-
ture to carry out the SNP to gene mapping: longer LD regions that contain many SNP will have
an advantage over shorter LD regions. A third type of bias is caused by treating markers in
high LD as independent GWAS hits [11,12]. For an LD region packed with several genes, this
approach will transfer a single association signal to multiple genes and can cause an artificial
positive inflation of the enrichment score for biological pathways which have several genes
clustered in the same LD region, as it often happens [21]. In this case, although only one path-
way gene may be associated with the trait, many genes will appear at the top of the GSEA
ordered list, causing a spurious enrichment for the entire pathway.
To control for such positive inflation, we can attempt to construct the ordered list for GSEA
by choosing only one gene from each LD region. The resulting list L in this case would
SJS/TENGenetic Susceptibility
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comprise a subset of genes, unlike the original GSEA method where all genes arrayed on the
gene expression microarray chip are used. A downside of this approach is that it can discrimi-
nate against pathways whose genes are under-represented in L. To avoid such discrimination,
Pointer builds a separate ordered list LP for each pathway P. Specifically, given the set GP of
genes in P, we process all snp-maps in order of increasing p-value of their representative SNP.
From each snp-map we randomly choose one gene to add to the ranked list LP, giving prefer-
ence to genes from GP in order to maximize the representation of GP in LP. After a snp-map
has been processed all its remaining genes are removed from the leftover snp-maps, thus mak-
ing them ineligible for inclusion in LP. As snp-maps are constructed to, effectively, span LD
regions, this procedure guarantees that only one gene per LD region is included in LP. Finally,
the GSEA gene set SP corresponding to P is defined as the subset of GP included in LP.
Genes in LP are ordered according to the GWAS p-value of the representative SNP of their
originating snp-map. The negative log of this p-value is used as the correlation metric in the
standard GSEA enrichment score (ES) calculation for SP [13]. A null distribution for ES is
empirically estimated by repeating the process described above for 1000 case/control label
shuffling permutations (S1 Fig). This permutation based procedure corrects for the length
biases identified previously (gene length and LD-region length) and for the preferential selec-
tion from GP when constructing LP. Additionally, the null distributions allow us to (1) compute
a normalized enrichment score (NES) that is comparable among gene sets of different size, and
(2) build a null distribution of NES that can be used to calculate a false discovery rate (FDR)
for any NES threshold. An illustration of the entire process is shown in Fig 1. Procedural details
of our GSEA adaptation can be found in the Supplementary Materials, S2 File.
Shadow and synergistic pathways
Compositional biases in pathway collections may lead to overrepresentation of particular bio-
logical processes, resulting in the inclusion of multiple functionally related pathways in the
pathway collection [12]. When the gene sets of two pathways overlap significantly, spurious
enrichment may occur if only one is involved in a particular phenotype. In this case, the other
pathway (called “shadow” pathway) can appear significantly enriched just because it shares a
large number of genes with the truly enriched one. Another possibility is that two pathways are
synergistically associated with a phenotype, i.e., that the intersection of the two pathways’ gene
sets is more “enriched than either gene set alone.
To identify both shadow and synergistic effects we used the method described in Lefebvre
et al. [22]. Specifically, we evaluated every pair of significantly enriched pathways
(FDR 0.25) by testing whether (1) either of them was no longer enriched after the overlap-
ping genes were excluded from the gene set (shadow effect), or (2) the set of their shared genes
was more enriched than any of the individual pathways (synergistic effect). Details of the pro-
cess are provided in the Supplementary Materials, S3 File.
Results
ABC transporters and Proteasome pathways are enriched in genetic risk
variants for SJS/TEN
837,175 SNPs passed the quality control filters applied to the genotypic data [10] and 423,718
were mapped to at least one gene by our SNP-to-gene mapping process (66,621 were assigned
to two or more genes). Using the logistic regression analysis results from [10] we applied
Pointer on all KEGG pathways comprising enough genes to satisfy the GSEA-recommended
minimum gene set size [23]; there were 153 such pathways. After controlling for spurious
SJS/TENGenetic Susceptibility
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enrichment (shadow analysis), we identified the ABC transporters, Proteasome and Propano-
ate metabolism as the top three most enriched pathways (FDR< 0.25; Table 1). The ABC
transporters pathway was the top enriched (p-value = 10−3 and FDR< 0.06). The QQ-plots
constructed for each pathway indicate that SNPs from the pathway genes are significantly
more associated with SJS/TEN than expected by chance (Fig 2 and S2 Fig). The lists of SNP-to-
GENEs and the associated p-value are reported in S1 Table.
The proteasome pathway is enriched in differentially expressed genes
from SJS active lesions
We used DAVID [17] to test for KEGG pathways enriched in a previously published list of 200
differentially expressed genes (DEGs) from SJS/TEN active lesions [3]. The Proteasome path-
way was identified as the most significantly enriched (FDR = 0.001, Table 2). Hierarchical clus-
tering of the expression profiles of the KEGG proteasome genes clearly delineated case and
control samples and demonstrated the up-regulation of the proteasome genes in the SJS/TEN
lesions (Fig 3). The overlap between the Pointer and the DAVID enrichment results was found
to be significant (Fisher’s exact text p-value of 0.03). This concordance of findings between the
Fig 1. Key steps of the Pointer algorithm.
doi:10.1371/journal.pone.0131038.g001
Table 1. The top enriched KEGG pathways for low risk genetic variants ranked by normalized enrichment score (NES).
Pathway #GSS #GLE ES NES PV FDR
ABC transporters 44 23 0.6 3.4 0.001 0.06
Proteasome 43 21 0.4 2.6 0.004 0.25
Propanoate metabolism 32 13 0.5 2.5 0.002 0.25
Abbreviations: #GSS (gene set size for the pathway); #GLE (number of pathway genes in GSEA leading edge); ES (enrichment score), NES (normalized
enrichment score), PV (p-value of ES), FDR (false discovery rate).
doi:10.1371/journal.pone.0131038.t001
SJS/TENGenetic Susceptibility
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SNPs and expression analyses provide additional evidence for the important role of the protea-
some complex in the pathogenesis of SJS/TEN.
The role of the proteasome genes in SJS/TEN
The proteasome complex genes were found to be enriched in SJS/TEN risk variants and were
also significantly up-regulated in the SJS/TEN skin active lesions. The complex is implicated in
several well-known biological processes, many of which are reported in the Reactome database.
Indeed, the database contains 24 proteasome complex-related pathways. Therefore, we applied
Pointer to the Reactome collection, aiming to more precisely characterize the proteasome com-
plex processes that are relevant for SJS/TEN susceptibility. Additionally, given that Reactome
Fig 2. QQ-plot (panel A) and GSEA plots (panel B) of the KEGGABC transporter pathway. The QQ-plot
is constructed using the genotyped SNPs whose snp-map contains at least one ABC transporter pathway
gene. The GSEA plot shows the enrichment score of the ABC transporter pathway. The top portion of the plot
shows the running enrichment score for the pathway genes as the analysis moves down the ranked list. The
peak score is the enrichment score for the gene set. The bottom portion of the plot shows the value of the
ranking metric as it moves down the list of ranked genes. The plots for the other two enriched pathways
(Proteasome and Propanoate metabolism) look similar (see S2 Fig).
doi:10.1371/journal.pone.0131038.g002
Table 2. The top KEGG pathways enriched in differentially expressed genes from SJS/TEN active lesions and ranked by FDR (FDR<0.25).
KEGG Pathways #GENES PV FE FDR
Proteasome (*) 6 0.00001 11.4 0.001
Lysosome 6 0.013 4.17 0.148
The enrichment score is computed by DAVID on the 200 DEGs from Chung et al. Abbreviations: #GENES (number of DEGs in the pathway), PV (p-value,
Fisher Exact test), FE (Fold Enrichment), FDR (false discovery rate). A (*) next to a pathway name indicates that the pathway was found to be enriched
by both Pointer and DAVID.
doi:10.1371/journal.pone.0131038.t002
SJS/TENGenetic Susceptibility
PLOS ONE | DOI:10.1371/journal.pone.0131038 June 25, 2015 7 / 15
contains a different set of biological processes than the ones found in KEGG, we reasoned that
Pointer might discover more enriched pathways. We note that the version of Reactome avail-
able through the MSigDB lacks pathways related to ABC transporter genes.
After shadow analysis we identified 11 significantly enriched pathways with FDR< 0.25
(Table 3). 10 of the 11 enriched pathways, including the top three, were proteasome complex-
related pathways. All of them were pairwise synergistic, each sharing 38 genes with the KEGG
proteasome complex. To investigate whether other genes, beyond the 38 shared genes, contrib-
uted appreciably to the enrichment of these 10 pathways we performed shadow analysis against
the KEGG proteasome complex pathway. Through this analysis we aimed to identify which
pathways were independently enriched due to variants in genes other than those in the KEGG
proteasome complex. Three of the 10 Reactome pathways were not shadowed by the KEGG
proteasome: (i) Apoptosis, (ii) cyclin E associated events during G1-S transition, and (iii) scf
beta trcp mediated degradation of emi1. The apoptosis pathway was also found to be
Fig 3. Hierarchical clustering of expression profiles for genes in the KEGG proteasome pathway. The
Hierarchical clustering analysis was performed on gene expression data from Chung et al., 2008. Individual
gene-related signals are increased (red), unchanged (white), or decreased (blue). The analysis clearly
separates cases (brown group) from controls (light blue group) and reveals the up-regulation of proteasome
genes in the SJS/TEN lesions.
doi:10.1371/journal.pone.0131038.g003
Table 3. Enriched Reactome pathways ranked by FDR.
Pathway GSS GLE ES NES PV FDR SD
CYCLIN E ASSOCIATED EVENTS DURING G1 S TRANSITION 58 30 0.40 3.49 0.001 0.08 0.12
REGULATION OF ORNITHINE DECARBOXYLASE 47 24 0.42 3.30 0.001 0.07 NA
APOPTOSIS 127 62 0.37 3.06 0.001 0.10 0.12
P53 INDEPENDENT DNA DAMAGE RESPONSE 43 21 0.41 2.99 0.003 0.09 NA
Generic transcription pathway 35 23 0.51 2.98 0.001 0.08 -
SCF BETA TRCP MEDIATED DEGRADATION OF EMI1 48 23 0.39 2.77 0.003 0.12 0.14
VIF MEDIATED DEGRADATION OF APOBEC3G 47 22 0.38 2.67 0.005 0.13 NA
STABILIZATION OF P53 46 21 0.38 2.63 0.005 0.13 NA
SCF SKP2 MEDIATED DEGRADATION OF P27 P21 52 21 0.36 2.59 0.005 0.13 0.07
G1 S TRANSITION 96 37 0.33 2.34 0.011 0.22 0.03
REGULATION OF APC ACTIVATORS BETWEEN G1 S AND EARLY ANAPHASE 71 26 0.33 2.26 0.016 0.23 0.03
In capital letters, pathways that contain KEGG proteasome genes.
Abbreviations: GSS (pathway gene set size); GLE (number of genes in leading edge); ES (Enrichment score), NES (Normalized Enrichment score), PV
(p-value), FDR (false discovery rate), SD (p-value of shadow analysis against KEGG proteasome pathway)
doi:10.1371/journal.pone.0131038.t003
SJS/TENGenetic Susceptibility
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significantly enriched in differentially expressed genes from SJS/TEN active lesions (DAVID
analysis, FDR = 0.05, Table 4).
We could not test the shadow effect for 4 of the 10 pathways because they had too few non-
proteasome genes (< 10). One among these four, the Regulation of ornithine decarboxylase,
was the only pathway that had a normalized enrichment score greater than that of the KEGG
proteasome (3.3 and 2.6, respectively) and did not have any overlapping genes with apoptosis,
cyclin E associated events during G1-S transition, and scf beta trcp mediated degradation of
emi1 beyond the KEGG proteasome genes. These findings suggest that the role of the protea-
some complex in the genetic susceptibility of the SJS/TEN may be a manifestation of the
genetic perturbation of specific biological processes (such as Apoptosis, cyclin E associated
events during G1-S transition, and scf-beta-trcp mediated degradation of emi1). Regulation of
ornithine decarboxylase may be also involved as it has a higher enrichment score than the
KEGG proteasome complex and its non-proteasome genes do not overlap with the other
pathways.
Impact of SNP-to-gene mapping on the power to detect pathway
enrichment
The SNP-to-gene mapping step in Pointer integrates information from both local LD structure
and liver eQTL data. To evaluate the benefits of this combined approach, we compared it with
two mapping strategies often used in other GSA methods: 1) Physical distance method: we
assigned each genotyped SNP to its closest gene by physical distance alone [24], 2) LD-recon-
struction method: we followed Pointer’s snp-map building process but excluded the eQTL data
[21]. In total we mapped respectively 357,097 SNPs and 416,812 SNPs to at least one gene. We
repeated our pathway enrichment analysis for these two SNP-to-gene maps. In both cases, con-
sidering an FDR< 0.25, no KEGG pathway was found to be significantly enriched (Table 5).
As these results suggest, increasing the information used at the SNP-to-gene mapping step
(from physical distance alone, to local LD structure, to LD structure plus eQTL data) leads to
improved power to detect enriched pathways, with the eQTL data seemingly having the largest
incremental impact. This finding corroborates recent observations that eQTLs are highly infor-
mative in interpreting GWAS results [25].
Table 4. The top REACTOME pathways enriched in differentially expressed genes from SJS/TEN active lesions and ranked by FDR (FDR<0.25).
Reactome Pathways #GENES PV FE FDR
DNA Replication 11 0.0009 3.51 0.009
Cell Cycle Checkpoints 8 0.001 4.65 0.014
Cdc20:Phospho-APC/C mediated degradation of Cyclin A 6 0.003 5.91 0.029
Immune System 22 0.003 1.91 0.029
Proteasome mediated degradation of PAK-2p34 5 0.004 7.08 0.046
Apoptosis (*) 8 0.005 3.65 0.052
Cell Cycle, Mitotic 12 0.007 2.49 0.066
HIV Infection 9 0.008 3.06 0.074
Signaling by Wnt 5 0.01 5.31 0.121
The enrichment score is computed by DAVID on the 200 DEGs from Chung et al. Abbreviations: #GENES (number of DEGs in the pathway), PV (p-value,
Fisher Exact test), FE (Fold Enrichment), FDR (false discovery rate). A (*) next to a pathway name indicates that the pathway was found to be enriched
by both Pointer and DAVID.
doi:10.1371/journal.pone.0131038.t004
SJS/TENGenetic Susceptibility
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Comparison with other GSAmethods
We benchmarked the performance of Pointer against 2 well-cited gene set enrichment meth-
ods: Magenta [26] and i-Gsea4gwas-V2 [27]. Both software tools were executed with default
parameter settings and using as input the SJS/TEN GWAS data and the KEGG pathway data-
base. The two algorithms utilize somewhat different approaches for the key GSA computa-
tional steps (SNP-to-gene mapping and testing for enrichment). Magenta maps SNPs to genes
by physical distance and, similar to Pointer, corrects for LD structure. Pathway enrichment is
estimated as the overrepresentation of leading edge genes relative to a permutation-based null
distribution. Magenta reported no significant pathways after correcting for multiple testing.
Although not overall significant, the ABC transporter and Proteasome pathways were among
the top four nominally enriched associated pathways (p-value = 0.036 –rank second, p-
value = 0.057—rank fourth, respectively; all p-values uncorrected). I-Gsea4gwas-V2 carries out
the SNP-to-gene mapping using only physical proximity information. It utilizes the Kolmogo-
rov–Smirnov test for computing enrichment and uses SNP label permutation to compute the
null score distribution. I-Gsea4gwas-v2 reported 15 enriched pathways at the 0.1 FDR level (S2
Table), including the ABC transporter pathway (nominal p-value = 0.004 and FDR = 0.05) but
not the proteasome pathway (nominal p-value = 0.152 and FDR = 0.5).
In summary, results from Pointer, Magenta, and i-Gsea4gwas-V2 point in the same direc-
tion, albeit with varying degrees of statistical strength. The ABC transporters and Proteasome
pathways consistently appear among the top scoring pathways. In the case of the Proteasome
pathway, enrichment is stronger when the SNP-to-gene mapping corrects for LD and inte-
grates eQTL data, underscoring the effect of using a more comprehensive mapping approach.
The inclusion of the eQTL data in particular, in conjunction with the use of a rigorous label
shuffling process for estimating the null distribution of enrichment scores, seems to confer an
appreciable power gain to Pointer compared to other approaches.
Discussion
We presented Pointer, a novel approach that integrates information from liver eQTLs and link-
age disequilibrium structure with GWAS association signals to aggregate the modest risk effect
of common genetic variants through canonical pathways. Applying Pointer, we identified a
number of pathways enriched in low risk variants, suggesting they may play a role in SJS/TEN
genetic predisposition across multiple drugs.
Pointer is a GSA-based approach that introduces several methodological innovations to
address known constraints and biases of enrichment analysis, thus significantly improving sta-
tistical power. There is strong evidence that SNPs associated with complex traits are most likely
acting by affecting gene regulation [25]. Motivated by this observation we used liver eQTL
information to capture regulatory pharmacogenetic variants. Existing GSA approaches map
Table 5. Comparison of False Discovery Rates from the pathway analysis performed with three SNP-
to-genemapping strategies.
Pathway FDR1 FDR2 FDR3
ABC transporters 0.86 0.64 0.06
Proteasome 0.98 0.68 0.25
Abbreviations: FDR1 (FDR from the pathway analysis performed using physical distance only), FDR2 (FDR
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SNPs to genes using either regulatory information [23,28] or physical distance [24,29]. By com-
bining these two mapping strategies we showed that Pointer improves the power of enrichment
analysis, even in studies with limited sample size. We demonstrated that our SNP-to-gene
mapping method was essential in detecting enrichment (Table 5). Additionally, we carefully
controlled for inflation of enrichment scores due to long LD regions that contain multiple
genes from the same pathway, by selecting only one representative gene per region. Finally, we
addressed compositional redundancy among gene sets by identifying spurious enrichments.
When Pointer was applied to the KEGG pathway collection it identified the ABC transport-
ers pathway (ABC-P) as the most significantly enriched in genetic variants associated with SJS/
TEN. The ABC-P is a collection of 44 genes from the same gene family. Genetic alterations in
several of these genes have been linked to congenital keratinization disorders such as Pseudox-
anthoma Elasticum (causal mutations in ABCC6), Harlequin ichthyosis (ABCA12) and lamel-
lar ichthyosis (ABCA12), a form of ichthyosis characterized by skin desquamation over the
whole body. [14] Notably, multidrug resistance transporters also belong to a subclass of this
family [30]. This suggests that multiple risk variants distributed across several of these genes
may contribute to SJS/TEN predisposition in a non-drug specific manner and may explain the
localization of the ADR target tissue.
Pointer also identified the proteasome complex and the propanoate metabolism pathways
as marginally enriched in low-risk variants. For the proteasome complex, independent func-
tional evidence further corroborated the role of the pathway in the pathogenesis of SJS/TEN.
Specifically, we showed that the pathway is enriched not only in genetic variants but also in
genes which are differentially expressed in blister cells from skin lesions of SJS-TEN versus
PBMCs [3]. As the proteasome complex participates in several biological processes that medi-
ate protein degradation, we further investigated if any of them are specifically implicated in
SJS/TEN. To that end we applied Pointer to the Reactome database which, to the best of our
knowledge, has the most comprehensive collection of Proteasome-related pathways. 10 of the
24 Reactome Proteasome-related pathways were identified as enriched by Pointer. For the
majority of them, enrichment was entirely due to genes shared with the KEGG proteasome
complex pathway. But for 3 pathways (Apoptosis, cyclin E associated events during G1-S tran-
sition, and, scf-beta-trcp mediated degradation of emi1) variants in genes other than those in
the KEGG proteasome complex were also significant contributors to the enrichment score.
This suggests that these pathways may represent specific biological processes through which
the proteasome complex is involved in the manifestation of SJS/TEN.
More broadly, there are at least two mechanisms that could explain the contribution of the
proteasome complex in the pathogenesis of SJS/TEN. First, proteasome mediated protein deg-
radation is a mechanism that is critically involved in generating the repertoire MHC-I pre-
sented peptides after interferon-γ activation [31,32,33]. Genetic determinants might control
the activity of the immune-proteasome in response to a drug-antigen. Second, proteasome-
mediated ubiquitin-dependent protein degradation is crucial for cell survival [34]. In particu-
lar, the activation of the proteasome seems to play a role in the cyclin-E dependent prolifera-
tion, activation and apoptosis of T lymphocytes and neutrophils [35,36]. Indeed, proteasome
inhibitors have been shown to induce the in vitro apoptosis of natural killer cells [37] (the
major effectors in the SJS immunoreaction) and to reduce T-cell dependent skin reaction in
Contact Hypersensitivity reactions in mice [38]. Therefore it seems plausible that genetically-
induced functional alterations in this complex and other apoptotic genes could increase the
hapten-specific survival of lymphocytes as well as the severity of the immunoreaction. This
hypothesis is supported by the fact that the apoptosis pathway was enriched both in risk vari-
ants as well as in differentially expressed genes. Further evidence for the genetic regulation of
neutrophil survival by the proteasome complex is provided by three large genome-wide
SJS/TENGenetic Susceptibility
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association studies which showed that neutrophil count is affected by genetic determinants in
PSMD3 (proteasome 26S subunit, non-ATPase, 3) [39,40], which regulate the expression of
the gene [40].
Finally, ornithine decarboxylase (ODZ) may also play a role in SJS/TEN predisposition. It
has been shown that an increase in the enzyme’s activity in keratinocites suppresses a classic
hapten induced immune-response in the context of Contact Hypersensitivity reactions [41].
The proteasome complex is involved in the degradation of ODZ and high expression of the
complex could lead to dysregulation of the lymphocytic immune response specifically on the
skin. In conclusion, we developed Pointer, an integrated pharmacogenetic GSA approach
which improves the power to detect the aggregate effect of common genotyped SNPs using
linkage data and liver-specific regulatory information. We applied this approach to publicly
available SJS/TEN GWAS data and we found that the ABC transporters and Proteasome path-
ways were significantly enriched in low-risk genetic variants. Moreover, proteasome genes
were highly expressed in activated lymphocytes collected from multi drugs SJS/TEN lesions.
This evidence suggests a role for the proteasome complex in the pathogenesis of blistering
lesions as well as in genetic predisposition to non-drug specific SJS/TEN. Further replication
and functional studies are needed to confirm these hypotheses.
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